UNITED THERAPEUTICS director exercises options, sells shares
UNITED THERAPEUTICS Corp director Christopher Causey exercised stock options and sold shares in a pre-planned transaction.
Rhea-AI Filing Summary
UNITED THERAPEUTICS Corp director Christopher Causey exercised stock options and sold shares in a pre-planned transaction. He exercised options for 1,300 shares of Common Stock at an exercise price of $119.76 per share and then sold 1,300 shares at $604.64 per share on the same date. These moves were executed under a Rule 10b5-1 trading plan entered into on September 30, 2025, indicating the trades were scheduled in advance. Following the transactions, he directly held 4,190 shares of Common Stock.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 1,300 shares ($630K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
CAUSEY CHRISTOPHER
Role
Director
Sold
1,300 shs ($786K)
Approx. gross sale proceeds
$786K
Approx. exercise cost
$156K
Approx. pre-tax spread
$630K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 1,300 | $0.00 | $0.00 |
| Exercise | Common Stock | 1,300 | $119.76 | $156K |
| Sale | Common Stock | 1,300 | $604.64 | $786K |
Holdings After Transaction:
Stock Option — 5,000 contracts (Direct);
Common Stock — 4,190 shares (Direct)
Footnotes (1)
- F1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on September 30, 2025.
Key Figures
Options exercised: 1,300 shares
Exercise price: $119.76 per share
Shares sold: 1,300 shares
+4 more
7 metrics
Options exercised
1,300 shares
Stock options exercised into Common Stock on March 30, 2026
Exercise price
$119.76 per share
Strike price of stock options exercised
Shares sold
1,300 shares
Common Stock sold in open-market transaction on March 30, 2026
Sale price
$604.64 per share
Price received per share in open-market sale
Shares held after
4,190 shares
Direct Common Stock holdings after reported transactions
Rule 10b5-1 plan date
September 30, 2025
Date trading plan governing these transactions was entered into
Option expiration
June 26, 2030
Expiration date of exercised stock options
Key Terms
Stock Option, open-market sale, Rule 10b5-1 trading plan, derivative security
4 terms
Stock Option financial
"security_title: "Stock Option" with exercise price $119.76 per share"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
open-market sale financial
"transaction_action: "open-market sale" for 1,300 Common Stock shares"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Rule 10b5-1 trading plan regulatory
"This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan"
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
derivative security financial
"transaction_code_description: "Exercise or conversion of derivative security""
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did UNITED THERAPEUTICS (UTHR) director Christopher Causey report in this Form 4?
Christopher Causey reported exercising stock options for 1,300 UNITED THERAPEUTICS shares at $119.76 and selling 1,300 shares at $604.64. The transactions were executed on March 30, 2026 under a pre-arranged Rule 10b5-1 trading plan.
At what price did Christopher Causey exercise his UNITED THERAPEUTICS (UTHR) stock options?
He exercised stock options for 1,300 UNITED THERAPEUTICS shares at an exercise price of $119.76 per share. These options were originally granted with an exercise date of June 26, 2021 and an expiration date of June 26, 2030.
Were Christopher Causey’s UNITED THERAPEUTICS (UTHR) trades pre-planned under a Rule 10b5-1 plan?
Yes. The filing states the option exercise and subsequent share sale were executed under a Rule 10b5-1 trading plan entered into on September 30, 2025. Such plans schedule trades in advance to promote systematic, non-discretionary transactions.
What type of transaction does code “M” indicate in this UNITED THERAPEUTICS (UTHR) Form 4?
Transaction code “M” in this Form 4 indicates the exercise or conversion of a derivative security, here stock options. Causey used it for exercising 1,300 options into Common Stock before selling the same number of shares in the open market.
AI-generated analysis. How Rhea-AI works. Not financial advice.
